Gland Pharma shares rose sharply after Q1FY27 profit rose 47% and revenue grew 20% year-on-year. While strong margins and CDMO growth prompted Elara Securities to raise its earnings estimates, the brokerage downgraded the stock to ‘Accumulate’ from ‘Buy’ after its 40% three-month rally, citing limited near-term upside.
Gland Pharma shares rose sharply after Q1FY27 profit rose 47% and revenue grew 20% year-on-year. While strong margins and CDMO growth prompted Elara Securities to raise its earnings estimates, the brokerage downgraded the stock to ‘Accumulate’ from ‘Buy’ after its 40% three-month rally, citing limited near-term upside.
<iframe src="https://hindustansphere.com/embed/cluster/43ee527d30531d2c2f970b1eacffcac4aa5c9a88" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Gland Pharma shares rally 12% after Q1FY27 profit jumps 47% YoY. Should you buy, sell or hold?"></iframe>
